Side-by-side · Research reference

ThymalinvsVilon

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AHuman-MechanisticAUTO-DRAFTED12/40 cited

BAnimal-StrongHUMAN-REVIEWED13/49 cited

Thymalin

Immune restorer · Russian peptide bioregulator

5–10 mgPer cycle doseKhavinson 2002

HumanMechanisticKhavinson 2002

HoursHalf-life (est)

IM · Daily for 5–10 days · 1-2×/year

Vilon

Khavinson Bioregulator · Dipeptide

2 AADipeptide

T-helperStimulatesLinkova 2011

MouseModel basisKhavinson 2002

Literature lacks standardised clinical route

01Mechanism of Action

Parameter

Thymalin

Vilon

Primary target

T-cell precursors + thymus-axis maturation pathwayKhavinson 2002

Immune cell differentiation pathways, chromatin modification

Pathway

Modulation of T-cell differentiation + thymic hormone restoration in age-involuted thymusKhavinson 2002

Vilon → Thymocyte sphingomyelinase activation → T-helper & cytotoxic T-cell differentiation; epigenetic suppression of aging markers (CCL11, HMGB1)

Downstream effect

Restored T-cell populations, improved immune surveillance, reduced infection rates in elderlyKhavinson 2002

Enhanced T-cell differentiation (CD4+, CD8+, B-cells), thymocyte proliferation, modulated IL-1β comitogenic activity, proposed chromatin decondensation in aged lymphocytesLinkova 2011 Khavinson 2002 Lezhava 2023

Feedback intact?

—

Unknown — no HPA/HPG axis data

Origin

Polypeptide fraction isolated from calf thymus extractKhavinson 2002

Synthetic dipeptide derived from Khavinson thymic peptide extraction studies (Thymalin fraction)Morozov 1997

Antibody development

—

02Dosage Protocols

Parameter

Thymalin

Vilon

Standard dose

5–10 mg / day IM × 5–10 daysKhavinson 2002

No clinical standard — literature lacks human dosing

Russian practice: often combined with other Khavinson peptides; no FDA/EMA trials.

Frequency

Once daily during cycle

Unknown — literature does not specify chronic administration protocols

Lower / starter dose

2.5 mg / day

—

Evidence basis

Russian clinical + in vitroKhavinson 2002

Mouse / in vitro only

Duration

5–10 day cycles, 1–2× per year

Not characterised in humans

Reconstitution

Saline or bacteriostatic water

—

Timing

Morning preferred

—

Half-life

Hours (estimated)

Not published — dipeptides typically <10 min plasma t½

Animal model dose

—

In vitro: 0.01–10 μg/mL culture medium (mouse thymocytes)

Not translatable to human mg/kg without pharmacokinetic data.

Route

—

Likely SQ or oral (Khavinson school uses both); no published ROA validation

04Side Effects & Safety

Parameter

Thymalin

Vilon

Injection site reaction

Mild erythema at IM site

—

Allergic reaction

Rare hypersensitivity to bovine-derived polypeptide

—

Autoimmune flare

Theoretical risk in active autoimmune disease

—

Long-term safety

Limited Western data

—

Pregnancy / OB

Avoid

—

Human safety data

—

Absent from PubMed-indexed literature

Theoretical risk

—

Immune hyperactivation in autoimmune-prone individuals (T-cell differentiation enhancement)

Antibody formation

—

Not reported; dipeptides generally low immunogenicity

Animal models

—

No adverse effects noted in mouse thymocyte or pineal lymphoid cultures

Absolute Contraindications

Thymalin

·Pregnancy / breastfeeding
·Bovine protein hypersensitivity

Vilon

·Active autoimmune disease (theoretical — no clinical data)

Relative Contraindications

Thymalin

·Active autoimmune disease
·Concurrent immunosuppressant therapy

Vilon

·Pregnancy / lactation (no safety data)
·Acute infection with cytokine storm risk (immune modulation unknown)

05Administration Protocol

Parameter

Thymalin

Vilon

1. Reconstitution

Add 1–2 mL saline or bacteriostatic water per 10 mg vial.

No clinical protocols exist in Western peer-reviewed literature. Russian gerontological practice may use 1–10 mg ranges, but dosing is empirical.

2. Injection site

Intramuscular — deltoid or gluteal. Rotate sites.

Subcutaneous injection (common for Khavinson peptides) or oral (some bioregulators reportedly active orally due to small size). No validated ROA.

3. Timing

Morning preferred during cycle.

Unknown — no circadian or meal-timing data. Khavinson school often recommends morning administration.

4. Storage

Lyophilised: refrigerate, light-protected. Reconstituted: use immediately.

Likely lyophilised powder, refrigerated. Reconstitution protocols not published.

5. Needle

23–25G, 25–38 mm IM needle.

—

06Stack Synergy

Thymalin

+ Thymosin α-1

Moderate

View Thymosin α-1 →

Thymalin is a polypeptide complex; Thymosin α-1 is a single purified peptide. Both target the thymus-axis but at different levels — Thymalin restores broad thymic signaling; Tα-1 provides a specific molecular activator. Anecdotally combined for elderly immune support.

Thymalin: 5–10 mg IM · daily × 7 days
Thymosin α-1: 1.6 mg SQ · 2× weekly during the cycle
Primary benefit: Broad thymic restoration + targeted immune activation

Khavinson 2002 Camerini 2001

Vilon

+ Epitalon

Moderate

View Epitalon →

Both are Khavinson bioregulators targeting aging pathways. Epitalon (Ala-Glu-Asp-Gly) acts on telomerase and pineal function; Vilon on immune differentiation and chromatin decondensation. Combined in Russian gerontological protocols for multi-system aging intervention. Lezhava et al. (2023) tested both on aged lymphocyte chromatin, showing distinct epigenetic effects. Complementary, not synergistic in strict pharmacological sense.

Vilon: Empirical — no standard
Epitalon: Empirical — often 10 mg cycles
Frequency: Sequential or concurrent (literature ambiguous)
Primary benefit: Multi-system aging modulation (immune + pineal/circadian)

+ Thymalin

Weak

View Thymalin →

Thymalin is the parent polypeptide complex from which Vilon was isolated. Both target immune differentiation, but Thymalin is a complex mixture (multiple peptides), whereas Vilon is a purified dipeptide. Morozov & Khavinson (1997) described Vilon as a synthetic successor designed to replicate Thymalin's immunomodulatory effects with greater specificity. Redundant in practice; no published combination studies.

Vilon: No standard
Thymalin: 10–100 mg IM (polypeptide complex)
Primary benefit: Redundant — both target T-cell differentiation

Morozov 1997 Khavinson 2020